| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1471-4159.2007.04743.X |
| P8608 | Fatcat ID | release_nh7w43dttrd2vkt5h4i5a3rrre |
| P932 | PMC publication ID | 2827244 |
| P698 | PubMed publication ID | 17623048 |
| P5875 | ResearchGate publication ID | 6215250 |
| P50 | author | Charles Warren Olanow | Q66933446 |
| Zhenyu Yue | Q67426069 | ||
| P2093 | author name string | Xin-Yun Huang | |
| Shibu Poulose | |||
| Xianting Li | |||
| Yin-Cai Tan | |||
| P2860 | cites work | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 |
| GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease | Q24294785 | ||
| The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity | Q24297634 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
| The Rab GTPase family | Q24542523 | ||
| GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins | Q24551119 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| LRRK2 in Parkinson's disease: protein domains and functional insights | Q28235024 | ||
| Interaction of Rac1 with GTPase-activating proteins and putative effectors. A comparison with Cdc42 and RhoA | Q28267082 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| A Rac-cGMP signaling pathway | Q30480019 | ||
| Roc, a Ras/GTPase domain in complex proteins | Q34280792 | ||
| Failure of the ubiquitin-proteasome system in Parkinson's disease | Q34325371 | ||
| BAC to the future: the use of bac transgenic mice for neuroscience research | Q34457226 | ||
| Biochemical and pathological characterization of Lrrk2. | Q40324969 | ||
| Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain | Q41695745 | ||
| Distribution of PINK1 and LRRK2 in rat and mouse brain | Q45859017 | ||
| Anatomical localization of leucine-rich repeat kinase 2 in mouse brain | Q46965681 | ||
| LRRK2 expression linked to dopamine-innervated areas | Q46987594 | ||
| The identification and characterization of an epidermal growth factor-stimulated phosphorylation of a specific low molecular weight GTP-binding protein in a reconstituted phospholipid vesicle system. | Q47447771 | ||
| Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome | Q48611307 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 238-247 | |
| P577 | publication date | 2007-07-10 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants | |
| P478 | volume | 103 |
| Q36497497 | A Drosophila model for LRRK2-linked parkinsonism |
| Q24296968 | A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity |
| Q24305448 | ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2 |
| Q26746897 | Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease |
| Q90292515 | Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies |
| Q89013363 | An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis |
| Q45817386 | Ancient origin of the Parkinson disease gene LRRK2. |
| Q24307742 | ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2 |
| Q24298093 | Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers |
| Q91741105 | CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain |
| Q40604356 | Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations |
| Q37686991 | Contribution of GTPase activity to LRRK2-associated Parkinson disease |
| Q26827527 | Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design |
| Q33565399 | Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect |
| Q33611632 | Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors |
| Q41812724 | Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation |
| Q37249125 | Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease. |
| Q21135493 | Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. |
| Q47139369 | Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers |
| Q28589899 | Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S |
| Q26772843 | Evaluation of Models of Parkinson's Disease |
| Q56422543 | Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate |
| Q34723024 | Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice |
| Q24294684 | Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system |
| Q47288069 | Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons. |
| Q49322801 | Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity |
| Q24310218 | Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily |
| Q50102071 | Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease |
| Q38814476 | GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2. |
| Q21144926 | GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1 |
| Q33553458 | GTPase activity plays a key role in the pathobiology of LRRK2. |
| Q37082055 | Gene-environment interactions in Parkinson's disease |
| Q33346009 | Genes associated with Parkinson syndrome |
| Q35148581 | Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications |
| Q22252904 | Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update |
| Q35067666 | Genetic variants ofLRRK2 in Taiwanese Parkinson's disease |
| Q38225040 | Genetic, structural, and molecular insights into the function of ras of complex proteins domains. |
| Q93175296 | HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice |
| Q27013695 | Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications |
| Q48450468 | Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease |
| Q28475942 | Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif |
| Q30596172 | Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations |
| Q28118311 | Inhibition of LRRK2 kinase activity stimulates macroautophagy |
| Q24306788 | Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant |
| Q38234885 | Interaction of LRRK2 with kinase and GTPase signaling cascades |
| Q27026262 | Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? |
| Q42737973 | Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities |
| Q55410950 | LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. |
| Q36981223 | LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease |
| Q38501861 | LRRK2 Pathways Leading to Neurodegeneration |
| Q58745072 | LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis |
| Q36385349 | LRRK2 autophosphorylation enhances its GTPase activity |
| Q37608626 | LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles |
| Q91646421 | LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function |
| Q38218398 | LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis |
| Q34079774 | LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease |
| Q37635000 | LRRK2: cause, risk, and mechanism |
| Q38009436 | Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease |
| Q33812599 | Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease |
| Q37829776 | Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? |
| Q37225356 | Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions |
| Q24303851 | Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export |
| Q33594388 | Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. |
| Q33636286 | Leucine-rich repeat kinase 2-linked Parkinson's disease: clinical and molecular findings |
| Q37531309 | Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. |
| Q24294736 | MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2 |
| Q36325784 | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. |
| Q37996364 | Mechanisms of LRRK2-mediated neurodegeneration. |
| Q24316270 | Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation |
| Q34986076 | Models for LRRK2-Linked Parkinsonism |
| Q40733668 | Multiple regulatory mechanisms for the Dictyostelium Roco protein GbpC. |
| Q24316917 | Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways |
| Q38268886 | Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression |
| Q36010883 | Number and brightness analysis of LRRK2 oligomerization in live cells |
| Q24338665 | Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain |
| Q64779059 | Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics |
| Q28115231 | Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation |
| Q34452296 | Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations |
| Q28586694 | Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease |
| Q59099056 | Physiological and pathological functions of LRRK2: implications from substrate proteins |
| Q27308060 | Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice |
| Q29347547 | Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity. |
| Q28067636 | Protein Kinases and Parkinson's Disease |
| Q47150726 | Rab29 activation of the Parkinson's disease-associated LRRK2 kinase |
| Q24298459 | Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2) |
| Q34109567 | Receptor-interacting protein (RIP) kinase family. |
| Q42111668 | Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease |
| Q39322027 | Regulation of LRRK2 promoter activity and gene expression by Sp1. |
| Q33470287 | Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP |
| Q60951726 | Roco Proteins and the Parkinson's Disease-Associated LRRK2 |
| Q34192817 | Role of LRRK2 kinase dysfunction in Parkinson disease |
| Q24651391 | Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells |
| Q42636181 | Sequence conservation between porcine and human LRRK2. |
| Q34706691 | Short- and long-term effects of LRRK2 on axon and dendrite growth |
| Q36015579 | Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. |
| Q38213378 | Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation |
| Q27649733 | Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase |
| Q27651307 | Structure of the Roc–COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase |
| Q91635012 | The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System |
| Q51093225 | The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2. |
| Q24324345 | The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation |
| Q24322927 | The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration |
| Q24313336 | The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites |
| Q64786590 | The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2 |
| Q33758163 | The R1441C mutation alters the folding properties of the ROC domain of LRRK2. |
| Q33521241 | The WD40 domain is required for LRRK2 neurotoxicity |
| Q33292556 | The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. |
| Q51275277 | The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro. |
| Q38111307 | The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease |
| Q36989256 | The roles of kinases in familial Parkinson's disease. |
| Q42116736 | The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease |
| Q35605204 | Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity |
| Q34890228 | Transgenic animal models of neurodegeneration based on human genetic studies. |
| Q36923141 | ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression |
| Q39206431 | Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. |
| Q34201811 | Unravelling the role of defective genes |
| Q37395783 | Update on the functional biology of Lrrk2. |
| Q92284349 | Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection |
| Q92017939 | What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations? |
| Q37363926 | What causes cell death in Parkinson's disease? |
| Q37313530 | Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. |
| Q38039369 | α-Synuclein and neuronal cell death |
| Q35100189 | α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease |
Search more.